15.63

0.13% 0.02

After Hours: 15.80 0.17 +1.09%

Novocure Ltd (NVCR)

Overview News Price History Option Chain Financials Why NVCR Down? Discussions Forecast

Novocure Ltd stock is traded at $15.63, with a volume of 501.68K. It is up +0.13% in the last 24 hours and down -19.60% over the past month. NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Previous Close:

$15.61

Open:

$15.52

24h Volume:

501.68K

Relative Volume:

0.39

Market Cap:

$1.69B

Revenue:

$525.66M

Net Income/Loss:

$-192.74M

P/E Ratio:

-8.4032

EPS:

-1.86

Net Cash Flow:

$-120.97M

1W Performance:

-5.44%

1M Performance:

-19.60%

6M Performance:

+0.00%

1Y Performance:

-3.22%

1-Day Range:

$15.34

$15.98

1-Week Range:

$15.34

$16.80

52-Week Range:

$10.87

$24.73

Novocure Ltd Stock (NVCR) Company Profile

Name

Novocure Ltd

Sector

Healthcare (1190)

Industry

Medical Devices (154)

Phone

44 (0)15 3475 6700

Address

NO. 4 THE FORUM, ST. HELIER

Employee

1,453

Twitter

@novocure

Next Earnings Date

2024-07-25

Latest SEC Filings

NVCR's Discussions on Twitter

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight
Aug-04-23	Initiated	SVB Securities	Outperform
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-05-23	Reiterated	H.C. Wainwright	Buy
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy
Feb-08-22	Initiated	Loop Capital	Buy
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-20-22	Upgrade	Truist	Hold → Buy
Jan-03-22	Upgrade	Evercore ISI	Underperform → In-line
Jul-01-21	Downgrade	Mizuho	Buy → Neutral
Apr-14-21	Downgrade	Wedbush	Neutral → Underperform
Jan-25-21	Reiterated	Piper Sandler	Overweight
Sep-23-20	Initiated	Northland Capital	Outperform
Sep-18-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-17-20	Downgrade	Truist	Buy → Hold
Jun-01-20	Resumed	Oppenheimer	Perform
May-01-20	Downgrade	Oppenheimer	Outperform → Perform
Apr-09-20	Downgrade	Evercore ISI	In-line → Underperform
Mar-05-20	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-02-20	Downgrade	Evercore ISI	Outperform → In-line
Jul-29-19	Upgrade	SunTrust	Hold → Buy
Jul-26-19	Downgrade	JP Morgan	Overweight → Neutral
Jul-26-19	Downgrade	Wedbush	Outperform → Neutral
Mar-20-19	Initiated	SunTrust	Hold
Nov-02-18	Downgrade	Wells Fargo	Outperform → Market Perform
Jul-16-18	Initiated	Evercore ISI	Outperform
Apr-18-18	Reiterated	Mizuho	Buy
Feb-23-18	Reiterated	Mizuho	Buy
May-24-17	Upgrade	Wells Fargo	Market Perform → Outperform
Jul-29-16	Reiterated	Wedbush	Outperform
Jan-19-16	Initiated	Barclays	Underweight
Dec-02-15	Initiated	Deutsche Bank	Hold

View All

Novocure Ltd Stock (NVCR) Latest News

11:27 AM

Balance Sheet Dive: NovoCure Ltd (NVCR)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

11:27 AM

09:57 AM

An analyst sees good growth prospects for NovoCure Ltd (NVCR) - SETE News

09:57 AM

05:19 AM

Novocure's SWOT analysis: oncology firm's stock faces growth hurdles, pipeline promise - Investing.com

05:19 AM

Sep 28, 2024

Hsbc Holdings PLC Sells 75,530 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat

Sep 28, 2024

Sep 26, 2024

A new trading data show NovoCure Ltd (NVCR) is showing positive returns. - SETE News

Sep 26, 2024

State of New Jersey Common Pension Fund D Makes New $1.45 Million Investment in NovoCure Limited (NASDAQ:NVCR) - MarketBeat

Sep 26, 2024

Sep 25, 2024

JP Morgan gives a Neutral recommendation for NovoCure Ltd (NVCR) - Knox Daily

Sep 25, 2024

Is NovoCure Ltd (NVCR) a good investment opportunity? - US Post News

Sep 25, 2024

Sep 24, 2024

In the Green: NovoCure Ltd (NVCR) Closes at 16.53, Up/Down -5.27 from Previous Day - The Dwinnex

Sep 24, 2024

Sep 23, 2024

Renaissance Technologies LLC Has $13.02 Million Position in NovoCure Limited (NASDAQ:NVCR) - Defense World

Sep 23, 2024

Sep 21, 2024

Seven Eight Capital LP Acquires New Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat

Sep 21, 2024

Sep 18, 2024

A company insider recently sold 688 shares of NovoCure Ltd [NVCR]. Should You also Consider to Sale? - Knox Daily

Sep 18, 2024

NovoCure (NASDAQ:NVCR) Shares Down 4% - MarketBeat

Sep 18, 2024

Analytical Lens: Exploring NovoCure Ltd (NVCR)’s Financial Story Through Ratios - The Dwinnex

Sep 18, 2024

A year in review: NovoCure Ltd (NVCR)’s performance in the last year - US Post News

Sep 18, 2024

Sep 16, 2024

Taking on analysts’ expectations and winning: NovoCure Ltd (NVCR) - SETE News

Sep 16, 2024

Sep 13, 2024

Chief Financial Officer Cordova Ashley sold 688 shares of NovoCure Ltd [NVCR] - Knox Daily

Sep 13, 2024

Sep 12, 2024

Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects - Simply Wall St

Sep 12, 2024

Sep 11, 2024